For the quarter ended June 2025, Guardant Health (GH) reported revenue of $232.09 million, up 31% over the same period last year. EPS came in at -$0.44, compared to -$0.48 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $211.43 million, representing a surprise of +9.77%. The company delivered an EPS surprise of +15.38%, with the consensus EPS estimate being -$0.52.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Oncology: $158.69 million versus the three-analyst average estimate of $153.38 million.
- Revenue- Licensing and other: $2.57 million versus $1.81 million estimated by three analysts on average.
- Revenue- Screening: $14.81 million versus the three-analyst average estimate of $8.31 million.
- Revenue- Biopharma and data: $56.02 million versus the three-analyst average estimate of $48.06 million.
View all Key Company Metrics for Guardant Health here>>>
Shares of Guardant Health have returned -14.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Guardant Health, Inc. (GH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
